These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21114486)

  • 1. Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1/2-test results.
    Vos J; Oosterwijk JC; Gómez-García E; Menko FH; Jansen AM; Stoel RD; van Asperen CJ; Tibben A; Stiggelbout AM
    Clin Genet; 2011 Mar; 79(3):207-18. PubMed ID: 21114486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.
    Vos J; Gómez-García E; Oosterwijk JC; Menko FH; Stoel RD; van Asperen CJ; Jansen AM; Stiggelbout AM; Tibben A
    Psychooncology; 2012 Jan; 21(1):29-42. PubMed ID: 21072753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life.
    Vos J; Otten W; van Asperen C; Jansen A; Menko F; Tibben A
    Psychooncology; 2008 Aug; 17(8):822-30. PubMed ID: 18157792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not.
    Vos J; Oosterwijk JC; Gomez-Garcia E; Menko FH; Collee MJ; van Asperen CJ; Jansen AM; Stiggelbout AM; Tibben A
    Patient Educ Couns; 2012 Feb; 86(2):239-51. PubMed ID: 21684708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment.
    Vos J; Menko FH; Oosterwijk JC; van Asperen CJ; Stiggelbout AM; Tibben A
    Psychooncology; 2013 May; 22(5):1167-76. PubMed ID: 22777929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives.
    Vos J; Menko F; Jansen AM; van Asperen CJ; Stiggelbout AM; Tibben A
    Fam Cancer; 2011 Mar; 10(1):87-96. PubMed ID: 20852944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' resistance to risk information in genetic counseling for BRCA1/2.
    Gurmankin AD; Domchek S; Stopfer J; Fels C; Armstrong K
    Arch Intern Med; 2005 Mar; 165(5):523-9. PubMed ID: 15767527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
    Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
    Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
    van Dijk S; Timmermans DR; Meijers-Heijboer H; Tibben A; van Asperen CJ; Otten W
    J Clin Oncol; 2006 Aug; 24(22):3672-7. PubMed ID: 16877736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Maheu C; Thorne S
    Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
    Dorval M; Gauthier G; Maunsell E; Dugas MJ; Rouleau I; Chiquette J; Plante M; Laframboise R; Gaudet M; Bridge PJ; Simard J
    Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2862-7. PubMed ID: 16365001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
    Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
    Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
    Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.